Barclays Boosts DaVita (NYSE:DVA) Price Target to $169.00

DaVita (NYSE:DVA - Free Report) had its target price lifted by Barclays from $164.00 to $169.00 in a research note published on Tuesday,Benzinga reports. Barclays currently has an equal weight rating on the stock.

DaVita Stock Performance

NYSE:DVA traded down $8.77 during mid-day trading on Tuesday, reaching $146.20. The stock had a trading volume of 1,412,108 shares, compared to its average volume of 795,084. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. The firm has a market capitalization of $11.70 billion, a price-to-earnings ratio of 13.57, a PEG ratio of 1.01 and a beta of 0.94. DaVita has a twelve month low of $119.42 and a twelve month high of $179.60. The business has a 50 day simple moving average of $161.40 and a 200 day simple moving average of $157.89.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported $2.24 EPS for the quarter, beating analysts' consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. On average, analysts expect that DaVita will post 10.72 earnings per share for the current fiscal year.

Institutional Investors Weigh In On DaVita

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. GF Fund Management CO. LTD. acquired a new stake in shares of DaVita during the 4th quarter valued at approximately $172,000. Neo Ivy Capital Management lifted its position in shares of DaVita by 191.1% during the 4th quarter. Neo Ivy Capital Management now owns 12,879 shares of the company's stock valued at $1,926,000 after acquiring an additional 8,455 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of DaVita by 14.0% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 466,046 shares of the company's stock worth $69,697,000 after purchasing an additional 57,386 shares in the last quarter. Worldquant Millennium Advisors LLC increased its stake in shares of DaVita by 154.4% during the 4th quarter. Worldquant Millennium Advisors LLC now owns 95,372 shares of the company's stock worth $14,263,000 after purchasing an additional 57,883 shares in the last quarter. Finally, Tidal Investments LLC increased its stake in shares of DaVita by 119.2% during the 4th quarter. Tidal Investments LLC now owns 12,466 shares of the company's stock worth $1,864,000 after purchasing an additional 6,778 shares in the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.